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The therapeutic action of a drug depends on its ability to engage with its molecular target in vivo.
However, current drug discovery strategies quantify drug levels within organs rather than deter-
mining the binding of drugs directly to their specific molecular targets in vivo. This is a particular
problem for assessing the therapeutic potential of drugs that target malignant tumors where access
and binding may be impaired by disrupted vasculature and local hypoxia. Here we have used
triple-negative human breast cancer cells expressing b2-adrenoceptors tagged with the biolumines-
cence protein NanoLuc to provide a bioluminescence resonance energy transfer approach to
directly quantify ligand binding to a G protein-coupled receptor in vivo using a mouse model of
breast cancer.
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G protein-coupled receptors (GPCRs) comprise the largest family of cell surface receptors involved in
signal transduction (Santos et al., 2017; Wacker et al., 2017). In recent years, there has been a realization
that a number of GPCRs may play important roles in cancer (Nieto Gutierrez and McDonald, 2018; De Fran-
cesco et al., 2017; Bar-Shavit et al., 2016; Liu et al., 2016; O’Hayre et al., 2013). For example, b-adrenocep-
tors are intimately involved in the pathogenesis of infantile hemangioma (Leaute-Labreze et al., 2008; Stiles
et al., 2012) and have been implicated in the progression of several malignant tumor types including angio-
sarcoma, breast cancer, and ovarian cancer (Rains et al., 2017; Watkins et al., 2015; Armaiz-Pena et al., 2013;
Choy et al., 2016; Le et al., 2016; Sloan et al., 2010). In particular, activation of b2-adrenoceptors by phys-
iological stress can switch cancer cells to an invasive metastatic phenotype (Sloan et al., 2010; Chang
et al., 2016; Creed et al., 2015). The classical b-adrenoceptor antagonist, propranolol, has clinical efficacy
for the treatment of infantile hemangiomas and angiosarcomas (Leaute-Labreze et al., 2008, 2015; Chow
et al., 2015; Stiles et al., 2013) and prevents the progression of cancer in mouse models (Sloan et al.,
2010) and in patients (Shaashua et al., 2017; De Giorgi et al., 2018).
Most cells in thebodyare close to vasculature allowingeasyaccessofdrugs fromcirculation.However, in tumors,
hypoxic regions and torturednon-functional vasculature (Folkman, 1971; Ferrara, 2001;Carmeliet and Jain, 2011;
Wong et al., 2015) result in a population of cells that are distant from blood vessels (Carmeliet and Jain, 2011;
MinchintonandTannock, 2006). This distancemayhinder theextent towhichdrugs reach these cells and interact
with theirmolecular target (Minchinton andTannock, 2006).However, upuntil now there has beenno simpleway
to visualize directly the extent to which target engagement has been achieved in vivo.
One approach to monitor ligand binding to GPCRs in living cells is through the use of fluorescent ligands
(Baker et al., 2011; Vernall et al., 2014; Stoddart et al., 2016). However, uptake into cells can often lead to
high levels of non-specific binding. We have recently dramatically improved the study of fluorescent ligand
binding by developing a bioluminescence resonance energy transfer (BRET) assay that requires close prox-
imity (circa 10 nm) between the fluorescent ligand and the target receptor to generate a measurable signal
(Stoddart et al., 2015, 2018). This has been achieved using GPCRs tagged with a very bright luciferase
(NanoLuc; Stoddart et al., 2015, 2018). This technological advance allowed us to monitor binding to the
human b2-adrenoceptor in real time using a red fluorescent analog of the antagonist propranolol, propran-
olol-(b-Ala-b-Ala)-X-BODIPY 630/650 (Prop-BY630; Stoddart et al., 2015; Figure S1). Here we have used this
fluorescent ligand in conjunction with a triple-negative human breast cell line (MDA-MB-231HM) expressing
an N-terminal NanoLuc-tagged human b2-adrenoceptor to quantify ligand binding (using NanoBRET) to a
GPCR in vivo using a mouse model of breast cancer.280 iScience 6, 280–288, August 31, 2018 ª 2018 The Author(s).
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Figure 1. Binding of Fluorescent Propranolol (Propranolol-(b-Ala-b-Ala)-X-BODIPY630/650; Prop-BY630) to
Triple-Negative Human Breast Cancer Cells (MDA-MB-231HM cells)
(A) Fluorescence imaging of the binding of 50 nM Prop-BY630 to non-transfected MDA-MB-231HM cells (upper panels) or
MDA-MB-231HM cells expressing NanoLuc-tagged human b2-adrenoceptors (lower panels). Cells were pre-treated with
Hoechst 33342 nuclear stain (2 mg/mL; blue labeling) and then labeled for 30 min with Prop-BY630 (red labeling). Upper
right and bottom right panels show cells pre-incubated with 10 mM unlabelled propranolol before labeling with
fluorescent propranolol (50 nM Prop-BY630). Cells were washed just before imaging to remove unbound fluorescent
ligand. Data are representative images from 3 independent experiments. Scale bar represents 50mm.
(B) Bioluminescence imaging (Olympus LV200) of NanoLuc-tagged b2-adrenoceptors. MDA-MB-231
HM Nluc-b2AR cells
treated with 400 nM furimazine substrate alone (upper panels) to detect luminescence in the absence of added
fluorescent ligand using an open channel (20 s exposure time; 420 nm longpass filter; upper left panel) or a Cy5 channel
(4 min exposure time; 600/50 nm bandpass filter; upper right panel) to detect BRET generated by binding of fluorescent
ligand, when present. Middle and lower panels show images from cells treated with 50 nM Prop-BY630, in the presence
(lower panels) or absence (middle panels) of unlabelled ICI 118551 (10 mM). Images shown were acquired with an open
channel (middle and lower left panels) and the Cy5 channel (middle and lower right panels). Scale bar represents 50 mm.
(C) BRET ratios obtained using bioluminescence imaging using ImageJ time series analyzer. Data show the mean and SE
obtained in 3 independent experiments. **p < 0.01 compared with basal or in the presence of 10 mM ICI 118551 (one-way
ANOVA with Tukey’s multiple comparisons).RESULTS AND DISCUSSION
Webegan by generating anMDA-MB-231HM cell line stably expressing the human b2-adrenoceptor with an
N-terminal NanoLuc tag. Standard fluorescence confocal microscopy revealed some of the limitations of
using a fluorescent probe without BRET (Figure 1A). Thus, following incubation with a fluorescent analog
of the b-blocker propranolol (50 nM; Prop-BY630; Figure S1), fluorescence was detected by confocal imag-
ing at both the cell membrane and in a discrete perinuclear region (Figure 1A; lower left panel). Cell mem-
brane fluorescence was completely prevented by co-incubation with 10 mM unlabelled propranolol
(Figure 1A; lower right panel), demonstrating specific binding of the ligand to the b2-adrenoceptors on
the cell surface. Perinuclear labeling, however, was not displaced by co-incubation with 10 mM unlabelled
propranolol indicating non-specific binding. Furthermore, only non-specific binding was detected in non-
transfected MDA-MB-231HM cells (Figure 1A; upper left panel). This demonstrates that although confocal
microscopy can detect cell surface receptors using fluorescent ligands, interpretation of the fluorescence
readout may be confounded in an in vivo setting by the extent of non-specific binding to non-receptor
sites.
To determine if BRET with NanoLuc-tagged receptors in combination with fluorescent ligands had the
specificity required to detect ligand-binding to GPCRs on the surface of cancer cells, we first used wide-
field bioluminescence imaging to demonstrate the cell membrane location of the NanoLuc-tagged b2-
adrenoceptor in MDA-MB-231HM cells (Figure 1B; left panels). Addition of 50 nM Prop-BY630 allowed us
to visualize the energy transfer from the N-terminal NanoLuc of the b2-adrenoceptor to the fluorescent
ligand bound to the receptor via NanoBRET (detected in the Cy5 channel). This clearly revealed specific
binding to cell surface b2-adrenoceptors that could be inhibited by a selective b2-antagonist ICI 118551
(10 mM; p < 0.001; Figures 1B and 1C). The BRET signal from this ligand-receptor interaction was also
measured in a 96-well plate format using a CLARIOstar plate reader, and demonstrated that the specific
binding detected by BRET increased with the concentration of the probe until all of the receptors on
the cell surface had been occupied. This specific binding (the difference between total binding andiScience 6, 280–288, August 31, 2018 281
Figure 2. Quantitative Analysis of Ligand Binding to NanoLuc-Tagged Human b2-Adrenoceptors Expressed in
MDA-MB-231HM Cells Using NanoBRET
(A) Binding of increasing concentrations of Propranolol-(b-Ala-b-Ala)-X-BODIPY630/650 (Prop-BY630) to NanoLuc-
tagged human b2-adrenoceptors in MDA-MB-231
HM cells measured using a CLARIOstar plate reader. Non-specific
binding was defined with 10 mM unlabelled ICI 118551. Data are mean G SE from 6 separate experiments. Total
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Figure 2. Continued
(open circles) and non-specific binding (closed circles) curves were fitted simultaneously as described in the
Transparent Methods. The dotted line shows the specific binding component derived from this analysis.
(B) Real-time kinetic analyses of Prop-BY630 binding to NanoLuc-tagged human b2-adrenoceptors expressed in
MDA-MB-231HM cells using 25, 50, 100, and 200 nM fluorescent ligand. BRET ratios for kinetic studies have been baseline-
corrected to specific binding (after subtraction of non-specific binding) at time 0. Data are mean G SE of triplicate
determinations in a representative experiment. Similar data were obtained in 4 additional experiments.
(C) Inhibition of the specific binding of 50 nM Prop-BY630 to NanoLuc-tagged human b2-adrenoceptors in MDA-
MB-231HM cells by increasing the concentrations of ICI 118551, un-labelled propranolol, and CGP20712A. Data are
mean G SE from 5 separate experiments.non-specific binding) was clearly saturable (pKD = 7.28G 0.07; n = 5; Figure 2A) and equally important for
the future in vivo experiments; non-specific binding to non-receptor sites (obtained in the presence of
10 mM ICI 118551) was very low (Figure 2A; closed circles).
To determine the compatibility for in vivo studies, we also imaged the BRET signal using a whole-animal
bioluminescence and fluorescence imaging system, IVIS Lumina II (Figure S2A), and obtained a compara-
ble pKD for fluorescent propranolol (7.26 G 0.06, n = 5). This was consistent with the value obtained pre-
viously for this ligand in HEK293 cells (Stoddart et al., 2015). The BRET methodology also allowed us to
determine the binding kinetics of fluorescent propranolol (kon 5.4 G 2.2 3 10
5 M1 min1; koff 0.025 G
0.004 min1; n = 5; Figure 2B). This confirmed that Prop-BY630 could bind rapidly to the b2-adrenoceptor,
but once bound dissociated slowly (the reciprocal of koff gives a residence time of 40min), making it an ideal
probe for in vivo use. Similar data for ligand binding kinetics/residence time were obtained in separate ex-
periments using the IVIS system (Figure S2B).
To ensure that the BRET signal detected was confined to the b2-adrenoceptor, competition-binding exper-
iments were undertaken with the b2-adrenoceptor-selective antagonist ICI 118 551, the b1-selective antag-
onist CGP 20712A (Gherbi et al., 2015), and the non-selective b-blocker propranolol (Figure 2C). These
experiments yielded pKi values that were consistent with literature values obtained previously for binding
to b2-adrenoceptors (Stoddart et al., 2015; Figures 2C, S2C, and S2D; Table S1). Thus, the b1-selective
antagonist CGP 20712A produced very little inhibition of fluorescent ligand binding at concentrations
up to 10 mM (Figure 2C). These data confirm that this BRET proximity assay is exquisitely selective and
only detects binding to NanoLuc-tagged b2-adrenoceptors expressed on the tumor cells. Furthermore,
our data also confirmed that the optical properties of the IVIS system had the sensitivity to detect ligand
binding to b2-adrenoceptors on cancer cells by BRET (Figure S2).
Previous work from our laboratory has shown that b2-adrenoceptors on MDA-MB-231
HM cells may play a
significant role in the effect of stress on metastasis (Le et al., 2016; Sloan et al., 2010; Chang et al., 2016).
Those studies used tumor cells that had been transfected with a cytosolic firefly luciferase marker to
monitor primary tumor growth and metastasis in a mouse model of breast cancer (Le et al., 2016; Sloan
et al., 2010; Chang et al., 2016). Cytosolic NanoLuc luciferase has also been used to monitor cancer pro-
gression in living animals (Stacer et al., 2013). In contrast, here we used receptor-specific NanoLuc biolu-
minescence to localize in vivo tumor cells that specifically express b2-adrenoceptors. In mice injected
with tumor cells into the mammary fat pad, luminescence intensity from NanoLuc-b2-adrenoceptors (pho-
tons/sec) increased from 8 days after tumor cell injection (Figures 3A and 3B) and correlated with primary
tumor size determined by caliper (mm3; Pearson correlation: p < 0.0001, R2 = 0.560; Figure 3A). Metastatic
tumors containing cells expressing b2-adrenoceptors appeared in the lung and axillary lymph nodes later in
tumor development (Figure 3C).
Todetect ligandbinding in vivobyBRETwe injectedProp-BY630 (0.1mg/kg)directly into the tumor (intratumoral
[IT]) and used the IVIS Lumina II imaging system to monitor the red fluorescence emission from the fluorescent
ligand relative to the blue luminescence donor emission from the NanoLuc-labeled b2-adrenoceptors. This
ratiometric approach determines the level of specific ligand binding independently of the number of cells ex-
pressing NanoLuc-b2-adrenoceptors present in the tumor. Thus, regardless of the slight variation in tumor
burden betweenmice, wewere able to compare howwell Prop-BY630 interactedwith the target b2-adrenocep-
tor on tumor cells. Preliminary experiments established that additionof 0.1mg/kgProp-BY630delivereddirectly
into the tumor reacheda steadyplateauBRET ratio, significantly abovebaseline values (n= 7;p< 0.001; two-way
ANOVA), within circa 15 min of administration of the fluorescent ligand (Figure S3).iScience 6, 280–288, August 31, 2018 283
Figure 3. Whole-Animal Bioluminescence Imaging of NanoLuc-b2AR MDA-MB-231
HM Tumor Growth and
Metastasis Development
(A) Female BALB/c nu/numice (7-week-old) were injected in the fourth left mammary fat pad with 53 105 MDA-MB-231HM
triple-negative human breast cancer cells that stably express the NanoLuc-tagged human b2-adrenoceptor. Tumor
development was monitored by bioluminescence imaging (left y axis) 5 min after IV injection of the NanoLuc substrate
furimazine (100 mL in PBS, circa 0.37 mg/kg) or by caliper measurements (right y axis) over 35 days.
(B) Representative bioluminescence images of primary tumors.
(C) Bioluminescencemonitoring of the development of metastasis in lungs and axillary lymph nodes. Inset: representative
images of lung and lymph nodemetastasis. Data were obtained from 11mice and are expressed as meanG SE. *p < 0.05,
**p < 0.005, ***p < 0.0001 (two-way ANOVA with Tukey’s multiple comparisons with respect to day 8 baseline). For
luminescence measurements, the statistical analysis was applied to the log transformed values.In a separate experiment with a crossover design, administration of the fluorescent ligand significantly
increased the BRET ratios for each mouse (measured after 1 hr), demonstrating detection of specific ligand
binding to b2-adrenoceptors (Figures 4A and 4C; p < 0.0001). Receptor engagement by the fluorescent
ligand was prevented by pre-treating mice with the b2-selective antagonist ICI 118551, delivered either
directly into the tumor (0.3 mg/kg IT p < 0.0001; Figures 4A and 4B) or through the tail vein (10 mg/kg intra-
venously [IV] p < 0.001; Figures 4C and 4D), demonstrating that the assay can be used to quantify the extent
to which unlabeled drugs (e.g., ICI 118551) can engage with their molecular target when delivered directly
into the tumor or through the circulation.
Drug-receptor engagement in the primary tumor region was also investigated for a lower dose of ICI
118551 administered IV (1 mg/kg), as well as for the b1-selective antagonist CGP20712A (10 mg/kg IV;
100 mL in PBS) (Figure 5). These experiments demonstrated that pre-treatment with CGP20712A produced
no significant attenuation of the specific binding of Prop-BY630 to b2-adrenoceptors on MDA-MB-231
HM284 iScience 6, 280–288, August 31, 2018
Figure 4. NanoBRET to Monitor Specific Ligand-Receptor Binding In Vivo in Primary MDA-MB-231HM Tumors
(A) Female BALB/c nu/nu mice (7-week-old) were injected in the fourth left mammary fat pad with 5 3 105 MDA-MB-231
triple-negative human breast cancer cells stably expressing Nluc-b2AR. Once tumor size reached >200 mm
3; BRET ratios
were determined from mice administered fluorescent propranolol-(b-Ala-b-Ala)-X-BODIPY630/650 alone (Prop-BY630 at
0.1 mg/kg intra-tumor, IT; red circles) or frommice receiving both Prop-BY630 (0.1 mg/kg IT) and 0.3 mg/kg ICI 118551 (IT;
blue circles). ICI 118551 was administered 45 min before the fluorescent propranolol. Control represents measurements
taken 5 min after IV injection (in 100 mL; circa 0.37 mg/kg) of the furimazine substrate 24 hr before administration of any
b2-adrenoceptor-directed ligands. BRET measurements of ligand binding were made 1 hr after injection of Prop-BY630
(treated condition). Furimazine substrate was injected IV 5 min before mice were imaged. Data represent meanG SE of
6 mice in each group. **p < 0.0001 (two-way ANOVA with Tukey’s multiple comparison test) compared with both control
datasets and the 1 hr treatment with Prop-BY630.
(B) Representative images showing singlemice exposed to Prop-BY630 only (left panel) or to 0.3 mg/kg (IT) ICI 118551 and
0.1 mg/kg (IT) Prop-BY630 (right panel). Upper panels shown in (B) show BRET images and lower panels show the total
bioluminescence (BLI) from the NanoLuc.
(C) BRET ratios determined frommice administered with fluorescent ligand alone (Prop-BY630 0.1mg/kg IT; red circles) or
from mice receiving both Prop-BY630 (0.1 mg/kg IT) and 10 mg/kg ICI 118551 (IV; blue circles). **p<0.0001 (two-way
ANOVA with Tukey’s multiple comparison test) compared with both control datasets. *p<0.001 compared to 1h
treatment with Prop-BY630.
(D) Representative images showing mice exposed to 0.1 mg/kg Prop-BY630 (IT) alone or to 10 mg/kg ICI 118551 (IV)
and 0.1 mg/kg Prop-BY630. Data represent mean G SE of 6 mice in each group.tumors in vivo, whereas a 10-fold lower dose of the b2-selective antagonist ICI 118551 produced a signif-
icant inhibition (p < 0.05; Figures 5; compare Figure 4B). These data demonstrate the ability of this assay
to accurately report target engagement in vivo. The data obtained with ICI 188551 indicate that 1 mg/kg
(IV) is a dose that achieves roughly 50% target engagement of tumor cell b2-adrenoceptors within this solid
breast cancer tumor model (Figure 5).
Finally, to establish the sensitivity of the assay to different doses of the fluorescent ligand, we monitored in
vivo ligand-binding BRET responses following addition of 0.01, 0.03, or 0.1 mg/kg of Prop-BY630 and quan-
tified the in vivo receptor residence times over 72 hr (Figure 6). These experiments demonstrated
significant ligand binding that could be detected by BRET with all 3 doses of the fluorescent ligand in a
dose-dependent manner (Figure 6). Furthermore, binding of each of the 3 doses of Prop-BY630 to tumor
b2-adrenoceptors was maintained for at least 48 hr after initial drug application (Figure 6). These data are
consistent with the slow off-rate kinetics of Prop-BY630 from the b2-adrenoceptor observed in vitro (Fig-
ure 2) and also suggest that the drug is not rapidly cleared from the tumor environment.
The close proximity requirements (10 nm) for BRET to occur between the donor NanoLuc on theN-terminus
of human b2-adrenoceptors on tumor cells and the receptor-bound Prop-BY630 therefore provides a very
sensitive and selective ligand binding assay to monitor receptor target engagement in tumors in vivo. As aiScience 6, 280–288, August 31, 2018 285
Figure 5. Effect of Selective b1- and b2-Adrenoceptor Antagonists on Prop-BY630 Binding to MDA-MB-231
HM
Cells In Vivo
Drug-receptor engagement in the primary tumor region was investigated using 0.1 mg/kg (IT) Prop-BY630 in mice treated
with the b2-selective antagonist ICI 118551 or the b1-selective antagonist CGP20712A. At 45 min before fluorescent ligand
injection, mice were administered (IV) with either PBS (100 mL), CGP201712A (100 mL; 10 mg/kg in PBS), or ICI 118551
(100 mL; 1 mg/kg in PBS). Data represent mean G SE of 6 mice in each group. Measurements were made 1 hr after
administration of Prop-BY630. Baseline measurements were obtained on the previous day in eachmouse when furimazine
was administered via the tail vein, but Prop-BY630 was not injected into the tumor. *p < 0.05 or #p < 0.001 with respect to
the baseline (t = 0) signal in each group. *p < 0.05 versus control Prop-BY630 binding (1 hr PBS). One-way ANOVA with
Tukey’s posthoc tests.consequence, the BRET readout should not be influenced by fluorescent ligand binding to neighboring
endogenous receptors on other cell types (e.g., vascular and immune cells) within the tumor microenviron-
ment. We therefore believe that this approach has significant advantages in specificity over other in vivo
imaging modalities such as positron emission tomography (Hazan et al., 2017) for the study of specific re-
ceptor target engagement in tumors.Figure 6. Dose-Dependent Binding of Prop-BY630 to b2-Adrenoceptors and Subsequent Ligand Dissociation
In Vivo
Tomonitor fluorescent ligand dissociation over time in the primary tumors, mice were administered with 3 different doses
of propranolol-(b-Ala-b-Ala)-X-BY630/650 (0.01, 0.03, or 0.1 mg/kg; IT). At 1, 24, 48, and 72 hr after fluorescent ligand
injection, mice were injected with furimazine substrate (IV, 100 mL in PBS, circa 0.37 mg/kg) and imaged 5 min later using
the IVIS Lumina II camera system. Imaging was performed by capturing sequential luminescence (open channel, 30 s
exposure time) and fluorescence (Cy5.5 channel, 5 min exposure times) images. All mice were also imaged on the day
before fluorescent ligand injection following an IV injection of furimazine to determine luminescence (and BRET) baseline
(t = 0). Data represent mean G SE of 6 mice in each group. *p < 0.05. **p < 0.01 or #p < 0.001 compared with
corresponding time 0 controls. Two-way ANOVA with repeated measures and Dunnett multiple comparisons.
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In summary, the present study has shown that ligand binding to a GPCR can be monitored in vivo using
BRET. Here we have used triple-negative human breast cancer cells expressing human b2-adrenoceptors
tagged with the bioluminescence protein NanoLuc to demonstrate that parenterally applied drugs can ac-
cess receptors on tumor cells in a mouse model of breast cancer. This in vivo NanoBRET method will be
widely applicable to monitor target engagement in animal models for other cell surface receptors such
as receptor tyrosine kinases (Kilpatrick et al., 2017) and for intracellular kinases (Robers et al., 2015).
Limitations of Study
The resolution of in vivo nanoBRET was limited in the present study to the detection of established tumors
including macro-metastases. Future development of fluorescent ligands with increased water solubility should
increase the stability in plasma and improve the detection of IV-administered probes. The development of new
nanoluciferase substrates should also improve the in vivo detection of resonance energy transfer.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, three figures, and one table and can be found
with this article online at https://doi.org/10.1016/j.isci.2018.08.006.
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Visualising ligand-binding to a GPCR in vivo using nanoBRET. 
 
Figure S1.  Reaction scheme for the synthesis of Propranolol-(β-Ala-β-Ala)-X-
BODIPY630/650 (Compound 8 in the figure; Prop-BY630). Related to Figure 1.  
Reagents and conditions: (a) tert-Butyl-2-aminoethyl carbamate (Boc), DMF/water (9:1), 
85oC, 16h, 39%; (b) 4M HCl in dioxane, 5h, 29-100%; (c) Boc-b-Ala-OH, HBTU, DIPEA, 
DMF, room temperature, 35-41%; (d) TFA, DCM, room temperature, 2h, 100%; (e) 
BODIPY630/650-X-SE, DIPEA, DMF, room termperature, 3h, 91%.  Abbreviations: BODIPY 
630/650-X-SE, 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)-
styryloxy)acetyl)aminohexanoic acid succinimidyl ester; DCM, dichloromethane; DIPEA, 
diisopropylethylamine; DMF, N,N-dimethylformamide; HBTU, N,N,N′,N′-Tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate; TFA, trifluoroacetic acid. 
 
 Figure S2. Quantitative analysis of ligand-binding to NanoLuc-tagged human β2-
adrenoceptors expressed in MDA-MB-231HM cells using BRET imaging with the IVIS 
Iumina II system. Related to Figure 2. (a) Binding of increasing concentrations of 
Propranolol-(β-Ala-β-Ala)-X-BODIPY630/650 (Prop-BY630) to NanoLuc-tagged human β2-
adrenoceptors in MDA-MB-231HM cells measured using the IVIS lumina II camera system. 
Non-specific binding was defined with 10µM unlabelled ICI 118551. Data are mean + S.E. of 
triplicate determinations in a representative experiment. Similar data were obtained in four 
further experiments. (b) Real time kinetic studies of Prop-BY630 binding to NanoLuc-tagged 
human β2-adrenoceptors expressed in MDA-MB-231HM cells using 25, 50, 100 and 200nM 
fluorescent ligand. Data are mean + S.E. of triplicate determinations in a representative 
experiment.  BRET ratios for kinetic studies have been baseline-corrected to the specific 
binding (after subtraction of non-specific binding) BRET ratio obtained at time zero. Similar 
data were obtained in two further experiments. (c) Inhibition of the specific binding of 50nM 
Prop-BY630 to NanoLuc-tagged human β2-adrenoceptors in MDA-MB-231HM cells by 
increasing concentrations of ICI 118551, propranolol and CGP20712A. Data are mean + 
S.E. from four separate experiments. (d) Representative plate image obtained using the IVIS 
system (using the Cy5.5 emission channel) for the competition binding assay shown in (c) 
with ICI 118551 (ICI), propranolol and CGP 20712A (CGP). 
  
 Figure S3. Time course of the binding of Prop-BY630 to β2-adrenoceptors in vivo. 
Related to Figure 4. Mice were injected with 0.1 mg/kg Propranolol-(β-Ala-β-Ala)-X-630/650 
(in 50µl of PBS) directly into the primary tumour (intratumoral; i.t). Immediately following this, 
mice were injected with 100µL 1:20 dilution furimazine substrate via the tail vein (i.v., 100µL 
diluted in PBS; circa 0.37 mg/kg) and imaged using the IVIS lumina II camera system. Mice 
were kept under 2-3% isoflurane anaesthesia during injections and imaging. Sequential 
luminescence (open channel, 30 sec exposure time) and fluorescence (Cy5.5. channel using 
660/20nm bandpass filter; 5 min exposure time) images were taken every 6 min for a total 
time of 49 min. Images were acquired from 1 min after fluorescent ligand injection. Values 
show mean + S.E from seven mice. 2-Way ANOVA confirmed that there was a significant 
time-dependent effect (p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table S1.  Table of pKi values obtained from competition experiments using the 
CLARIOstar plate reader or the IVIS imaging camera system.   Related to Figure 2. 
 
Equilibrium binding parameters obtained from inhibition of the specific binding of 50nM Prop-
BY630 to NanoLuc-tagged human β2-adrenoceptors in MDA-MB-231HM cells by increasing 
concentrations of ICI 118551 and un-labelled propranolol. Data are mean + S.E. from n 
separate experiments.  
 
  
Unlabelled 
Ligands 
CLARIOStar 
pKi  (mean ± S.E) 
n IVIS 
pKi  (mean ± S.E) 
n 
ICI 118551 8.55 ± 0.05 5 8.55 ± 0.02 4 
Propranolol 8.68 ± 0.17 5 8.69 ± 0.18 4 
TRANSPARENT METHODS 
Experimental Procedures. 
Synthesis of Propranolol-b-ala-b-ala-BODIPY 630/650.  
Propranolol-(b-alanine,b-alanine)-X-BODIPY630/650 (Stoddart et al., 2015; Soave et al., 
2016) was synthesised as described in the reaction scheme in Supplementary Figure S1. 
Chemicals and solvents of analytical and HPLC grade were purchased from commercial 
suppliers and used without further purification. BODIPY-630/650-X-SE was purchased from 
Molecular Probes (Thermo Fisher Scientific). All reactions were carried out at ambient 
temperature unless otherwise stated. Reactions were monitored by thin-layer 
chromatography on commercially available silica pre-coated aluminium-backed plates 
(Merck Kieselgel 60 F254). Visualisation was under UV light (254 nm and 366 nm), followed 
by staining with ninhydrin or KMnO4 dips. Flash column chromatography was performed 
using silica gel 60, 230-400 mesh particle size (Sigma Aldrich). NMR spectra were recorded 
on a Bruker-AV 400. 1H spectra were recorded at 400.13 Hz and 13C NMR spectra at 101.62 
Hz. All 13C NMR are 1H broadband decoupled. Solvents used for NMR analysis (reference 
peaks listed) were CDCl3 supplied by Cambridge Isotope Laboratories Inc., (δH = 7.26 ppm, 
δC = 77.16) and CD3OD supplied by VWR (δH = 3.31 ppm and δC = 49.00). Chemical shifts 
(δ) are recorded in parts per million (ppm) and coupling constants are recorded in Hz. The 
following abbreviations are used to described signal shapes and multiplicities; singlet (s), 
doublet (d), triplet (t), quadruplet (q), broad (br), dd (doublet of doublets), ddd (double 
doublet of doublets), dtd (double triplet of doublets) and multiplet (m). Spectra were 
assigned using appropriate COSY and HSQC experiments. Processing of the NMR data 
was carried out using the NMR software Topspin 3.0. LC-MS spectra were recorded on a 
Shimadzu UFLCXR system coupled to an Applied Biosystems API2000 and visualised at 
254 nm (channel 1) and 220 nm (channel 2). LC-MS was carried out using a Phenomenex 
Gemini-NX C18 110A, column (50 mm × 2 mm x 3 μm) at a flow rate 0.5 mL/min over a 5 
min period (Method A). All high resolution mass spectra (HRMS) were recorded on a Bruker 
microTOF mass spectrometer using MS electrospray ionization operating in positive ion 
mode. RP-HPLC was performed on a Waters 515 LC system and monitored using a Waters 
996 photodiode array detector at wavelengths between 190 and 800 nm. Spectra were 
analysed using Millenium 32 software. Semi-preparative HPLC was performed using YMC-
Pack C8 column (150 mm × 10 mm × 5 μm) at a flow rate of 5.0 mL/min using a gradient 
method of 40-95% B over 15 minutes (Solvent A = 0.01% formic acid in H2O, solvent B = 
0.01% formic acid in CH3CN (Method B)). Analytical RP-HPLC was performed using a YMC-
Pack C8 column (150 mm × 4.6 mm × 5 μm) and a Phenomenex Gemini NX-C18 column 
(250 mm × 4.6 mm × 5 μm) at a flow rate of 1.0 mL/min. Final products were one single 
peak and >95% pure. The retention time of the final product is reported using a gradient 
method of 5-95% solvent B in solvent A over 25 minutes. (Solvent A = 0.01% formic acid in 
H2O, solvent B = 0.01% formic acid in CH3CN (Method C)). 
Abbreviations; BODIPY 630/650-X-SE, 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-
indacene-3-yl)-styryloxy)acetyl)aminohexanoic acid succinimidyl ester; DCM, 
dichloromethane; DIPEA, diisopropylethylamine; DMF, N,N-dimethylformamide; HBTU, 
N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate; TFA, 
trifluoroacetic acid. 
 (±)-2-((Naphthalen-1-yloxy)methyl)oxirane (1) 
The title compound was synthesised as previously described in the literature (Baker et al., 
2011). 
(±)-tert-Butyl 2-(2-hydroxy-3-(naphthalen-1-yloxy)propylamino)ethylcarbamate (2) 
A solution of (±)-2-((naphthalen-1-yloxy)methyl)oxirane (1) (0.241 g, 1.20 mmol) and tert-
butyl-2-aminoethylcarbamate (0.482 g, 3.01 mmol) in a mixture of DMF/water 9:1 (6 mL), 
was heated at 85°C for 16 hours. The solvent was removed under reduced pressure and the 
crude product was purified by column chromatography on silica (3% 1M NH3 in 
MeOH/DCM). The title compound was afforded as an off-white solid (0.168g, 39%). 1H NMR 
(400 MHz, CDCl3) δ 8.30 – 8.18 (m, 1H), 7.84 – 7.76 (m, 1H), 7.54 – 7.41 (m, 3H), 7.36 (dd, 
J = 8.3, 7.5 Hz, 1H), 6.82 (dd, J = 7.6 Hz, J = 1.0 Hz, 1H), 4.95 (t, J = 5.3 Hz, 1H), 4.28 – 
4.22 (m, 1H), 4.22-4.11 (m, 2H) 3.34 – 3.22(m, 2H) 3.00 (dd, J = 12.3, 3.7 Hz, 1H), 2.92 (dd, 
J = 12.2, 7.5 Hz, 1H), 2.83 (ddd, J = 6.2, 1.5 Hz, 2H), 1.44 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 156.41, 154.36, 134.63, 127.68, 126.60, 125.94, 125.65, 125.45, 121.91, 120.85, 
105.08, 70.62, 68.59, 53.57, 51.90, 49.52, 28.55. LC-MS m/z calc. for C20H29N2O4 [MH]+; 
361.2, found; 361.2, tR = 2.29 min. 
(±)-2-(2-Hydroxy-3-(naphthalen-1-yloxy)propyl-amino)ethylamine dihydrochloride (3) 
To a solution of (±)-tert-butyl 2-(2-hydroxy-3-(naphthalen-1-yloxy)propyl-
amino)ethylcarbamate (2) (0.063 g, 0.18 mmol) in Et2O (0.5 mL) 4M HCl in dioxane (0.5 mL) 
was added and the mixture was stirred for 5 hours. The solvent was removed under reduced 
pressure to afford the title compound as a pale pink solid (0.060 g, 100%). 1H NMR (400 
MHz, CD3OD) δ 8.36 – 8.26 (m, 1H), 7.86 – 7.78 (m, 1H), 7.58 – 7.43 (m, 3H), 7.39 (dd, J = 
8.3, 7.6 Hz, 1H), 6.95 (dd, J = 7.6 Hz, 1H), 4.64-4.41 (m, J = 9.8 Hz, 1H), 4.27 (dd, J = 10.0, 
5.0 Hz, 1H), 4.21 (dd, J = 10.0, 5.5 Hz, 1H), 3.57 – 3.45 (m, 3H), 3.43 – 3.35 (m, 3H). 13C 
NMR (101 MHz, CD3OD) δ 155.35, 136.08, 128.59, 127.51, 126.92, 126.79, 126.28, 122.80, 
121.98, 106.16, 71.05, 66.84, 51.97, 45.82, 36.69. LC-MS m/z calc. for C15H21N2O2 [MH]+; 
261.2, found; 261.2, tR = 0.62 min. 
(±)-tert-Butyl(3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-
oxopropyl)carbamate (4) 
To Boc-β-Ala-OH (0.090 g, 0.47 mmol) in DMF (2 mL) HBTU (0.213 g, 0.56 mmol) and 
DIPEA (0.302 g, 2.34 mmol) were added. The mixture was stirred for 10 minutes and (±)-2-
(2-Hydroxy-3-(naphthalen-1-yloxy)propyl-amino)ethylamine dihydrochloride (3) (0.060 g, 
0.18 mmol) in DMF (1.5 mL) was added. After stirring for 2 hours the reaction mixture was 
partitioned between EtOAc and a 1:1 mixture of sat. NaHCO3 (aq)/water. The aqueous layer 
was washed with EtOAc x2 and the combined organic phases were dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude material was purified by 
column chromatography (10% 1M NH3 in MeOH/DCM) to afford the title compound as a 
colourless oil (0.072 g, 35%). 1H NMR (400 MHz, CDCl3) δ 8.27 – 8.18 (m, 1H), 7.85 – 7.73 
(m, 1H), 7.58 – 7.41 (m, 3H), 7.39-7.31 (m, Hz, 1H), 6.80 (d, J = 7.5 Hz, 1H), 6.56 (s, 1H), 
5.30 (s, 1H), 4.45-4.25 (m, 1H), 4.25 – 4.08 (m, 2H), 3.48-3.41 (m, 2H), 3.41-3.33 (m, 2H), 
3.12 -2.78 (m, 4H), 2.43-2.34 (m, 2H), 1.41 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 172.52, 
154.21, 134.63, 127.71, 126.65, 125.95, 125.58, 125.51, 121.85, 120.97, 105.11, 70.43, 
51.78, 50.99, 48.95, 36.71, 28.54. LC-MS m/z calc. for C23H34N3O5 [MH]+; 432.2, found; 
432.2, tR = 2.25 min. 
(±)-3-((2-((2-Hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-
oxopropylamine ditrifluoroacetate (5) 
To a solution of (±)-tert-butyl(3-((2-((2-hydroxy-3-(naphthalen-1-
yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)carbamate (4) (0.072 g, 0.17 mmol) in DCM 
(0.5 mL), TFA (0.5 mL) was added. The mixture was stirred at room temperature for 2 hours 
and the solvent was then removed under reduced pressure to afford the title compound as 
an off-white viscous solid which was used directly in the next step (0.054 g, 100%).  LC-MS 
m/z calc. for C23H34N3O5 [MH]+; 332.2, found; 322.1. LCMS tR = 0.98 min. 
(±)-tert-Butyl-(3-((3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-
oxopropyl)amino)-3-oxopropyl)carbamate (6) 
The synthesis of the title compound 6 was carried out as described for (±)-tert-butyl(3-((2-
((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)carbamate (4), 
using (±)-3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-
oxopropylamine ditrifluoroacetate (5). The title compound was afforded as an off-white 
viscous solid (0.034 g, 41%). 1H NMR (400 MHz, CD3OD) δ 8.34 – 8.25 (m, 1H), 7.85 – 7.76 
(m, 1H), 7.56 – 7.44 (m, 3H), 7.43 – 7.35 (m, 1H), 6.94 (dd, J = 7.6, 1.0 Hz, 1H), 4.53 - 4.43 
(m, 1H), 4.26 (dd, J = 9.9, 5.0 Hz, 1H), 4.20 (dd, J = 9.9, 5.6 Hz, 1H), 3.58 – 3.41 (m, 4H), 
3.36 – 3.34 (m, 2H), 3.29 – 3.24 (m, 4H), 2.44-2.26 (m, 4H). 13C NMR (101 MHz, CD3OD) δ 
180.17, 155.35, 155.01, 136.08, 135.11, 130.26, 128.58, 127.51, 127.51, 126.92, 126.79, 
126.28, 125.33, 122.79, 121.98, 118.74, 118.31, 106.16, 71.05, 66.84, 51.97, 45.82, 36.69. 
LC-MS m/z calc. for C26H39N4O6 [MH]+; 503.3, found; 503.3, tR = 2.25 min. 
(±)-3-((3-((2-((2-Hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-
oxopropyl)amino)-3-oxopropylamine dihydrochloride (7) 
Deprotection of (±)-tert-butyl-(3-((3-((2-((2-hydroxy-3-(naphthalen-1-
yloxy)propyl)amino)ethyl)amino)-3-oxopropyl)amino)-3-oxopropyl)carbamate (6) (0.082 g, 
0.16 mmol) was carried out as described for the synthesis of (±)-2-(2-Hydroxy-3-
(naphthalen-1-yloxy)propyl-amino)ethylamine dihydrochloride (3). The title compound was 
afforded as a white solid (0.019 g, 29%). 1H NMR (400 MHz, CD3OD) δ 8.35-8.26 (m, 1H), 
7.92 – 7.74 (m, 1H), 7.57 – 7.43 (m, 3H), 7.39 (dd, J = 8.3, 7.5 Hz, 1H), 6.95 (d, J = 7.6 Hz, 
1H), 4.48 (dtd, J = 9.8, 4.9, 3.0 Hz, 1H), 4.33 – 4.13 (m, 2H), 3.77 – 3.70 (m, 1H), 3.69 – 
3.63 (m, 2H) 3.61 – 3.55 (m, 2H), 3.48 (t, J = 6.4 Hz, 3H), 3.41-3.32 (m, 1H), 3.18 (t,  J = 6.5 
Hz, 2H), 2.60 (t, J = 6.5 Hz, 2H), 2.45 (t, J = 6.5 Hz, 2H), 1.41 – 1.35 (m, 1H). 13C NMR (101 
MHz, CD3OD) δ 175.66, 172.33, 155.40, 136.05, 128.54, 127.49, 126.93, 126.81, 126.28, 
122.88, 121.90, 106.16, 71.15, 68.13, 66.86, 51.53, 37.16, 37.11, 37.06, 36.76, 33.00, 
32.32. LC-MS m/z calc. for C21H31N4O4 [M+H]+; 403.3, found; 403.3, tR = 0.91 min. 
N-(3-((3-((2-((2-Hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-
oxopropyl)amino)-3-oxopropyl)-6-((4-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-
bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxy)acetamido)-hexanamide (8, 
propranolol-β-Ala-β-Ala-X-BODIPY630/650) 
To (±)-3-((3-((2-((2-hydroxy-3-(naphthalen-1-yloxy)propyl)amino)ethyl)amino)-3-
oxopropyl)amino)-3-oxopropylamine dihydrochloride (7) (2.2 mg, 4.54 µmol) in DMF (0.2 
mL), DIPEA (1.98 µL, 11.40 µmol) was added and then BODIPY 630/650-X-SE (1.5 mg, 
2.27 µmol) dissolved in DMF (0.8 mL) was added. The mixture was stirred with the exclusion 
of light for 3 hours. The solvent was removed under reduced pressure and the crude 
material was purified by semi-preparative HPLC (Method B) to give the title compound as a 
blue solid (2.0 mg, 91%). Analytical RP-HPLC tR = 19.68 min, purity = 98% HRMS (ESI-TOF) 
m/z calc. for C50H57BF2N7O7S [M+H]+; 948.4098 found; 948.4096 and 970.3929 [M+Na]. 
 
cDNA Construct. 
The b2-adrenoceptor cDNA sequence (obtained from Missouri S&T cDNA Resource Centre; 
www.cdna.org) was PCR amplified to generate a b2-adrenoceptor sequence that was in 
frame with the BamH1 restriction site of sig-NLuc (Stoddart et al., 2015) and sig-SNAP 
(Gherbi et al., 2015) and changed the start codon (Met) of the b2-adrenoceptor sequence to 
Leu.  The primers used were: forward 5’-CCGCCGGATCCCTGGGGCAACCCGGGAACG-3’ 
and reverse 5’-GGCGGGAATTCTTACAGCAGTGAGTCATTTG-3’. The PCR product was 
then ligated in frame into pcDNA3.1(+) containing sig.SNAP3 or sig-NLuc1 using BamHI and 
EcoRI restriction enzymes. This created the plasmids sig-SNAP-ADRB2-pcDNA3.1(+) and 
sig-NLuc-ADRB2-pcDNA3.1(+). 
The pSIN-SNAP-ADRB2 construct was generated on the basis of pSIN-eGFP-BSD lentiviral 
vector (Dixon et al., 2011) as following:  first, the pSIN-eGFP-BSD plasmid was digested 
with SpeI and EcoRI restriction enzymes in order to remove eGFP sequence and to produce 
the pSIN/BSD backbone; second, SNAP-ADRB2 fragment was PCR amplified with  5’-
CTTAAACTAGTTACCGCCACCATGCGGCTCTGC-3’ (forward) and  5’-
TCTGCAGAATTCttacagcagtgagtcatttg-3’ (reverse) primers using sig-SNAP-ADRB2-
pcDNA3.1(+) as a template. The resulting PCR product was digested with SpeI and EcoRI 
restriction endonucleases and ligated into eGFP-free pSIN/BSD backbone. To make the 
pSIN-NLuc-ADRB2 construct, a NheI-EcoRI fragment containing the NanoLuc-ADRB2 
fusion sequence was isolated from sig-NLuc-ADRB2-pcDNA3.1(+) and used to replace 
SpeI-EcoRI SNAP-ADRB2 sequence in pSIN-SNAP-ADRB2. 
Cancer cell model. 
This study used a highly metastatic variant of the female MDA-MB-231 triple-negative 
human breast cell line (MDA-MB-231HM; a kind gift from Dr. Zhou Ou, Fudan University 
Shanghai Cancer Center, China) (Chang et al., 2008). Cell line identity was confirmed by 
short tandem repeat analysis. The cell line was stably transfected with the lentiviral vector 
pSIN-NLuc-ADRB2 encoding Nanoluc-β2-adrenoreceptor (Nluc-β2AR), using FugeneHD 
reagent, following the manufacturer’s protocol, using a 3:1 reagent:DNA ratio. Transfected 
cells were selected using 20 µg/mL blastocidin (Sigma).  10 µg/mL blastocidin was used for 
cell maintenance. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 2mM Glutamax (Gilbco) supplemented with 10% foetal bovine serum.  For in vivo 
use, blastocidin was removed from the growth medium for several passages. 
Confocal microscopy. 
Confocal microscopy was performed using a Leica TCS SP8 inverted scanning microscope 
with a Zeiss 40x 1.3NA oil immersion HCPL APO CS2 objective lens. Untransfected MDA-
MB-231HM cells or MDA-MB-231HM cells expressing NanoLuc-tagged b2-adrenoceptors were 
seeded in eight-well chambered coverslip slides (µSlide; Ibidi, Martinsried, Germany). Prior 
to imaging, media was replaced with Hank’s buffered salt solution (HBSS) (Gibco, Thermo 
Fisher) pH 7.2-7.4, at 37oC. Cells were incubated in HBSS for 10 min with the nuclear stain 
Hoechst 33342 (2 μg/mL), and then washed twice with HBSS. Cells were then treated with 
50nM propranolol-(β-Ala-β-Ala)-X-BODIPY630/650, in the presence or absence of 
unlabelled propranolol (10µM), and incubated for 30 min at 37oC (without CO2). Cells were 
washed with HBSS to remove unbound ligand before imaging. Nuclear labelling was 
detected using a 405nm-Argon laser line (415-470nm bandpass), and fluorescent ligand 
labelling was detected using a 633nm HeNe laser line and a 640-700 bandpass filter. 
Images were analysed using ImageJ 1.51 (Fiji, USA) software.  
Widefield bioluminescence microscopy. 
Bioluminescence imaging was performed using an Olympus LV200 Wide field inverted 
microscope, equipped with a 60x/1.42NA oil immersion objective lens. MDA-MB-231HM cells 
transfected with NanoLuc-tagged human β2-adrenoceptors were seeded into a 35mm 
MatTek dish containing a high tolerance 1.5μm coverslip. Before imaging, media was 
removed and cells were incubated with 2mL HBSS containing 400nM furimazine substrate 
(Promega) at 37oC, for 15 min. Background luminescence images were taken by capturing 
sequentially luminescence in the following channels: (1) open channel (20 sec exposure 
time); (2) DAPI channel (20 sec exposure time; 420nm longpass filter) and (3) Cy5 channel 
(4 min exposure time; 600/50nm bandpass filter). Cells were then incubated for 30 min with 
50nM propranolol-(β-Ala-β-Ala)-X-BODIPY630/650, in the presence or absence of 10 μM ICI 
118551, before images were acquired using the same acquisition sequence. BRET ratio 
measurements were performed using ImageJ 1.51 (National Institutes of Health, USA) and 
the time-series analyser V3 plugin.   
In vitro NanoBRET assays. 
Saturation, competition and kinetics NanoBRET binding assays were performed on MDA-
MB-231HM cells stably expressing NanoLuc-tagged b2-adrenoceptors as described 
previously (Stoddart et al., 2015). Briefly, cells were seeded 24h before assay in white 
Perkin Elmer 96-well Isoplates. For experiments performed under equilibrium conditions, 
growth media was replaced with 100μL HBSS. Fluorescent and non-fluorescent ligands 
were added simultaneously and the 96-well plate was incubated for 1h at 37 °C (no CO2). 
10μL NanoLuc substrate furimazine (Promega) was then added to give a final concentration 
of 10µM and the plate was incubated for a further 5 minutes at 37 °C.  For all experiments, 
the luminescence was measured using a CLARIOstar plate reader (BMG Labtech) with 
filtered light emission collected at 685nm/100nm bandpass (acceptor) and 460nm/80nm 
bandpass (donor) at room temperature. The raw BRET ratio was calculated by dividing the 
685nm emission by the 460nm emission. The same experiments were also performed using 
the IVIS Lumina II whole-animal imaging system (Caliper Life Sciences, Perkin Elmer) using 
both an open channel (donor; 1 sec exposure time) and the CY5.5 channel (acceptor; 
660/20nm bandpass; 30 sec exposure time). 
For kinetics binding assays, growth media from cells was replaced with 50μL HBSS 
containing 10μM furimazine substrate, and incubated for 15 min, at 37oC (without CO2). 
50μL ligands, previously prepared in HBSS, were then added to wells and luminescence 
measurements were made every minute (for 60 min) with the above emission settings on 
both the CLARIOstar plate reader and the IVIS Lumina II system as described above.  
Breast cancer in vivo model. 
5x105 (in 20µl PBS) MDA-MB-231HM triple negative human breast cancer cells stably 
expressing Nanoluc-β2-adrenoceptors were injected (Hamilton syringe with 26.5G needle) 
into the fourth left mammary fat pad of female BALB/c nu/nu immune-compromised mice (7-
week-old) (University of Adelaide, Australia). Mice were housed under PC2 barrier 
conditions on a 12 h dark/light cycle and monitored daily. Primary tumours were measured 
by caliper and volume (mm3) was calculated by the formula: (length x width2)/2.  Mice were 
maintained under 2-3% isoflurane anaesthesia during injections and imaging. All in vivo 
procedures were carried out at Monash Institute of Pharmaceutical Sciences according to 
protocols approved (MIPS.2012.11) by the Monash University Animal Ethics Committee and 
according to the NHMRC (Australia) guidelines. 
 Bioluminescence imaging to monitor tumour and metastasis development. 
The growth of solid tumours and the extent of metastasis were monitored by whole-animal 
bioluminescence imaging. The luminescence from the NanoLuc-b2-adrenoceptors on MDA-
MB-231HM cells was monitored using an IVIS Lumina II camera system equipped with a 
heated stage (37oC). On the day of imaging, mice were anaesthetised with 2-3% isoflurane 
and then injected via the tail vein (i.v.) with 100µl Nano-Glo® luciferase substrate 
(furimazine, diluted in PBS; circa 0.37 mg/kg). Whole-animal images were taken 5 min after 
substrate injection (open channel; 30 sec exposure time). Immediately afterwards, images of 
metastasis localised in the thorax region were also taken. Images of the thorax were 
acquired 10 min after furimazine injection, using luminescence imaging (open channel; 2 min 
exposure time). 
In vivo NanoBRET. 
i) Monitoring fluorescent ligand-receptor association in the primary tumour 
In preliminary experiments to monitor ligand-receptor association in vivo, mice were firstly 
injected with 0.1 mg/kg Propranolol-(β-Ala-β-Ala)-X-630/650 (in 50µl of PBS) directly into the 
primary tumour (intratumoral; i.t). Immediately after fluorescent ligand injection, mice were 
injected with 100µL 1:20 dilution furimazine substrate via the tail vein (i.v., 100µL diluted in 
PBS; circa 0.37 mg/kg) and imaged using the IVIS lumina II camera system. Mice were kept 
under 2-3% isoflurane anaesthesia during injections and imaging. Sequential luminescence 
(open channel, 30 sec exposure time) and fluorescence (Cy5.5. channel using 660/20nm 
bandpass filter; 5 min exposure time) images were taken every 6 min for a total time of 49 
min. Images were acquired from 1 min after fluorescent ligand injection. 
ii) Monitoring fluorescent ligand-receptor dissociation in the primary tumour 
To monitor fluorescent ligand dissociation over-time in the primary tumour region, mice were 
administered with one of three different doses of Propranolol-(β-Ala-β-Ala)-X-630/650 (0.01, 
0.03 or 0.1 mg/kg). At 1, 24, 48 and 72h after fluorescent ligand injection, mice were injected 
with furimazine substrate (i.v., 100µL in PBS, circa 0.37 mg/kg) and imaged 5 min later using 
the IVIS lumina II camera system. Sequential luminescence (open channel, 30 sec exposure 
time) and fluorescence (Cy5.5 channel, 5 min exposure times) images were acquired at 1h, 
24h, 48h and 72h after fluorescent ligand injection (i.t.). All mice were also imaged on the 
day before fluorescent ligand injection, 5 min after 100µL i.v. injection with furimazine 
substrate (1:20 dilution in PBS) to determine luminescence (and BRET) baseline.  
iii) Monitoring ligand-receptor engagement of unlabelled drugs administered locally 
in the primary tumour (i.t.) or via intravenous injection (i.v.) 
To monitor specific ligand-receptor engagement of the unlabelled β2-selective antagonist, ICI 
118551, administered locally in the primary tumour (i.t.), mice were divided into two groups: 
Group 1 received an intra-tumour (i.t. 0.1 mg/kg; 50µL in PBS) injection of the fluorescent 
ligand alone and Group 2 received 0.3 mg/kg (i.t.; 50µL in PBS) ICI 118551 45 min prior to 
injection of 0.1 mg/kg Propranolol-BY630 (i.t.). 1h after the fluorescent ligand injection 
luminescence/fluorescence images were captured on the IVIS lumina II instrument 
(NanoLuc donor open channel, 30 sec exposure time; BRET acceptor Cy5.5 channel, 
660nm/20nm band pass, 5 min exposure time), 5 min after furimazine injection (100µL in 
PBS; circa 0.37 mg/kg). Mice were imaged on the previous day 5 min after an equivalent 
furimazine i.v. injection to determine luminescence (and BRET) baseline. After 10 days, 
when fluorescent ligand was no longer detected by imaging, the treatment schedule was 
reversed. Group 1 mice were injected with 0.3 mg/kg ICI 118551 plus 0.1 mg/kg 
Propranolol-BY630/650, while Group 2 animals were injected with fluorescent ligand alone.  
To investigate drug-receptor engagement in the primary tumour region following parenteral 
administration (i.v.) of the selective β2-selective antagonist ICI 118551 (100µl in PBS; 10 
mg/kg) a similar cross over experimental design was followed with 0.1 mg/kg propranolol-(β-
Ala-β-Ala)-X-BODIPY630/650 injected directly into the primary tumour 45 min after i.v. 
administration of ICI 118551. Mice were also imaged on the previous day, 5 min after i.v. 
injection of furimazine to determine luminescence (and BRET) baseline. Images were 
acquired as described above using the IVIS system, 5 min after furimazine substrate (100µL  
in PBS; 0.37 mg/kg) injection, using the same filter settings and exposure times as 
described above for the donor and acceptor readings.  
Drug-receptor engagement in the primary tumour region was also investigated for a lower 
dose of ICI 118551 administered i.v. (1 mg/kg), as well as for an unlabelled β1-selective 
antagonist, CGP20712A administered i.v. (10 mg/kg; 100µL in PBS). In these experiments, 
mice were administered with fluorescent ligand (0.1 mg/kg i.t.; 50µL in PBS). 45 min prior to 
fluorescent ligand injection, mice were administered (i.v.) with either PBS (100µL), 
CGP201712A (100µL; 10 mg/kg in PBS), or ICI 118551 (100µL; 1 mg/kg in PBS). Images 
were acquired 1h after fluorescent ligand injection, as described above. All mice were also 
imaged on the previous day, 5 min after i.v. injection with furimazine substrate (1:20 dilution, 
circa 0.37 mg/kg) to determine luminescence (and BRET) baseline.  BRET ratios were 
calculated after dividing acceptor/donor emissions (photons/sec), determined using regions 
of interest (ROIs) drawn over the tumour site.  
Data analysis. 
In vitro pharmacological characterisation. 
For analysis of saturation binding data, raw BRET ratios obtained from each individual 
experiment were fitted using a non-linear regression equation shown below, using GraphPad 
Prism 7.  Total and non-specific binding curves were fitted simultaneously using the 
following equation: 
𝐵𝑅𝐸𝑇	𝑅𝑎𝑡𝑖𝑜 = 	𝐵+,- × [𝐵][𝐵] +	𝐾3 +	4(𝑀	 × [𝐵]) + 𝐶9 
where Bmax is the maximal binding, [B] is the concentration of fluorescent ligand, KD is the 
equilibrium dissociation constant, M is the slope of the non-specific binding component and 
C is the intercept with the Y-axis. 
Competition binding curves were fitted to the following equation using Prism 7: %	𝑢𝑛𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑒𝑑	𝑏𝑖𝑛𝑑𝑖𝑛𝑔 =	 (BCCDEF)([G] HIJK⁄ )MB + 𝑁𝑆  
where [A] is the concentration of unlabelled, IC50 is the molar concentration of the unlabelled 
ligand required to inhibit 50% of the specific binding of 50nM propranolol-(β-Ala-β-Ala)-X-
BODIPY630/650 and NS represents non-specific binding.  
The Cheng Prusoff equation was then used to convert IC50 values to absolute Ki values: 𝐾P = HIJKBM [Q]RS  
where [L] is the concentration of labelled ligand and KD is the dissociation constant of the 
fluorescent ligand obtained from saturation binding assays. pKi values were then calculated 
as –log Ki. 
 
Data obtained for fluorescent ligand binding kinetics, using more than one concentration, 
were globally fitted to an association kinetics model. The kinetic rate constants: koff 
(dissociation rate constant of the ligand; min-1) and kon (association rate constant; M-1 min-1) 
were calculated from the following equation: 
𝑘UV 	= 	𝑘UWX −	𝑘UZZ[𝐿]  
where [L] is the fluorescent ligand concentration and kobs is calculated from global fitting of 
the data to the following monoexponential association function: 𝑌 =	𝑌+,-(1 − 𝑒D^_`ab) 
where Y is the specific binding at time t, 𝑌𝑚𝑎𝑥 corresponds to the level of specific binding at 
infinite time and 𝑘UWX  is the rate constant for the observed rate of association.  
In vivo data analysis. 
In vivo luminescence or fluorescence total flux (photons/sec) measurements were obtained 
using ROIs positioned on the primary tumour or thorax region, for primary tumour or 
metastasis measurements, respectively. Raw BRET ratios were calculated as: 𝐵𝑅𝐸𝑇	𝑟𝑎𝑡𝑖𝑜 = 	 GffghbUi	jk+PVgXfgVfg	(Ilm.m)3UVUi	jk+PVgXfgVfg	(UhgV	fo,VVgp)  
where acceptor luminescence (Cy5.5 channel) is measured as total flux (photons/sec) 
acquired using the Cy5.5 emission channel (660nm/20nm bandpass), and luminescence 
(open channel) is measured as total flux (photons/sec) acquired without using emission 
filters. 
Statistical analysis. 
For in vitro and in vivo studies, one-way or two-way ANOVA analysis with Tukey’s or 
Dunnett’s multiple comparison tests were used.  
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